LiquidChromatographyof

Anticonvulsantsin an inappropriatelyDrawn (Lipemic) Serum Sample
To the Editor:
Inevitably, blood samples for drug analysis will occasionally be drawn from an inappropriate site. Here we illustrate how such samples can be handled.
A 21-year-old woman was admitted to the hospital for surgical repair of tongue and facial lacerations, multiple fractures of the mandible, a right pneumothorax, and left lateral malleous fracture, all incurred in an auto accident. Three months earlier, the patient had undergone a craniotomy for removal of posterior fossa glioma, and she was taking phenytoin and phenobarbital at the time of the accident.
While she was in hospital, phenytoin, 100 mg twice daily, and phenobarbital, 30 mg twice daily, were continued. Three days after surgery, Intralipid, a commercially available intravenous fat emulsion, was started for nutritional support at a rate of 40 mL/hour. The next day, blood was drawn for determination of phenytoin and phenobarbital "trough"
concentrations.
When the sample was received at the laboratory it was noted that the serum appeared "milky," closely resembling serum from hyperlipidemic patients. Investigation revealed that the nurse had drawn the blood from a site just above the Intralipid intravenous site.
We routinely use a modification of the HPLC procedure of Kabra et al. To confirm that the anticonvulsant assay values by the new extraction procedure were similar to the values obtained on using only deproteinization, we obtained another (this time appropriately-drawn) blood sample exactly 24
h after the lipemic sample. Again, we assayed a serum control at the same time, after protein precipitation.
The results of the anticonvulsant analysis (Table 1) demonstrate that the concentrations of phenytoin and phenobarbital in the patient's serum and the control serum, measured after extraction, were nearly identical to the concentrations measured after deproteinization.
The differences in results between the extracted samples and the deproteinized samples did not exceed the quality control limits of the assay and were negligible.
The extraction procedure described here is a useful alternative to deproteinization and direct injection, at least for sera phenytoin and phenobarbital analysis by liquid chromatography. Without an extraction step, the lipemic sample produced interfering peaks on the chromatogram which resulted in a two-to threefold overestimation of the actual concentrations of phenobarbital and phenytoin.
